NO934851L - Fremgangsmåte for stimulering av immunrespons - Google Patents

Fremgangsmåte for stimulering av immunrespons

Info

Publication number
NO934851L
NO934851L NO934851A NO934851A NO934851L NO 934851 L NO934851 L NO 934851L NO 934851 A NO934851 A NO 934851A NO 934851 A NO934851 A NO 934851A NO 934851 L NO934851 L NO 934851L
Authority
NO
Norway
Prior art keywords
immune response
stimulating immune
igf
stimulating
immune
Prior art date
Application number
NO934851A
Other languages
English (en)
Other versions
NO934851D0 (no
Inventor
Ross G Clark
Paula M Jardieu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO934851D0 publication Critical patent/NO934851D0/no
Publication of NO934851L publication Critical patent/NO934851L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Vessels, Lead-In Wires, Accessory Apparatuses For Cathode-Ray Tubes (AREA)
  • Signal Processing Not Specific To The Method Of Recording And Reproducing (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Fremgangsmåte for stimulering av et pattedyrs eller en fugls immun-respons, særlig immunkompromitterte pattedyr, ved administrering av IGF-I, alene eller i kombinasjon med veksthor-mon. Den anvendte IGF-I er fortrinnsvis en fullt ferdig, human IGF-I med natur-lig forekommende sekvens.
NO934851A 1991-06-28 1993-12-27 Fremgangsmåte for stimulering av immunrespons NO934851L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/722,813 US5202119A (en) 1991-06-28 1991-06-28 Method of stimulating immune response
PCT/US1992/005189 WO1993000110A1 (en) 1991-06-28 1992-06-16 Method of stimulating immune response

Publications (2)

Publication Number Publication Date
NO934851D0 NO934851D0 (no) 1993-12-27
NO934851L true NO934851L (no) 1994-02-25

Family

ID=24903495

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934851A NO934851L (no) 1991-06-28 1993-12-27 Fremgangsmåte for stimulering av immunrespons

Country Status (14)

Country Link
US (2) US5202119A (no)
EP (1) EP0602050B1 (no)
JP (1) JPH06508830A (no)
AT (1) ATE152627T1 (no)
AU (1) AU655059B2 (no)
CA (1) CA2109705A1 (no)
DE (1) DE69219607T2 (no)
DK (1) DK0602050T3 (no)
ES (1) ES2101106T3 (no)
FI (1) FI935898A (no)
GR (1) GR3024128T3 (no)
NO (1) NO934851L (no)
NZ (1) NZ243232A (no)
WO (1) WO1993000110A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US5744139A (en) * 1991-06-28 1998-04-28 University Of Tennessee Research Corporation Insulin-like growth factor I (IGF-1) induced improvement of depressed T4/T8 ratios
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
WO1994016722A1 (en) * 1993-01-25 1994-08-04 The Beth Israel Hospital Association Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
AU6449894A (en) * 1993-03-19 1994-10-11 Michael M. Rothkopf Nutrient formulations and methods of treating malnutrition in aids
GB9310049D0 (en) * 1993-05-12 1993-06-30 Cancer Res Campaign Tech Growth factor effects
EP0726911B1 (en) * 1993-09-20 2002-10-30 Celtrix Pharmaceuticals, Inc. Treatment of hematologic disorders with a igf-1/igfbp-3 complex
US5661122A (en) * 1994-04-15 1997-08-26 Genentech, Inc. Treatment of congestive heart failure
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
SE9402370D0 (sv) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
AUPM678294A0 (en) * 1994-07-13 1994-08-04 Gropep Pty Ltd Use of insulin-like growth factor in combination with insulin
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5948757A (en) * 1996-03-01 1999-09-07 Celtrix Pharmaceuticals, Inc. High dose IGF-1 therapy
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
WO1998016244A1 (fr) * 1996-10-16 1998-04-23 Sumitomo Pharmaceuticals Company, Limited Medicament utilise comme adjuvant dans l'hypothermie
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
EP1016414B1 (en) * 1998-12-17 2004-09-08 Applied Research Systems ARS Holding N.V. Human growth hormone to stimulate hematopoiesis and immune reconstitution after hematopoietic stem cell transplantation in humans
PT1141014E (pt) * 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
EP1292330A1 (en) * 2000-03-31 2003-03-19 Vaccine Chip Technology APS Immunostimulating properties of a fragment of tgf- beta
US20030190322A1 (en) * 2000-03-31 2003-10-09 Peter Kaastrup Immunostimulating properties of a fragment of tgf-beta
EP1282437B1 (en) 2000-05-16 2008-03-19 Genentech, Inc. Treatment of cartilage disorders
ATE439378T1 (de) * 2001-02-09 2009-08-15 Genentech Inc Verfahren zur identifizierung von indirekten igf- 1-agonisten
US7326417B2 (en) * 2001-09-11 2008-02-05 Merial Ltd. IGF-1 as feline vaccine adjuvant, in particular against feline retroviruses
FR2829498B1 (fr) * 2001-09-11 2003-11-28 Merial Sas Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
CN101022820A (zh) * 2004-08-30 2007-08-22 特西卡股份有限公司 诊断和治疗胰岛素样生长因子缺陷疾病的方法和装置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189426A (en) * 1976-04-12 1980-02-19 Hoffmann-La Roche, Inc. Recombinant hormonal compositions and method
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4898830A (en) * 1979-07-05 1990-02-06 Genentech, Inc. Human growth hormone DNA
US4621053A (en) * 1980-07-30 1986-11-04 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Process for the production of human peptide hormones
US4446235A (en) * 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
US4755465A (en) * 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US4859600A (en) * 1983-04-25 1989-08-22 Genentech, Inc. Recombinant procaryotic cell containing correctly processed human growth hormone
US4791099A (en) * 1984-10-29 1988-12-13 Chaovanee Aroonsakul Method of treatment for central nervous system diseases such as Alzheimer's's disease
JPH0720993B2 (ja) * 1985-08-22 1995-03-08 グロペップ プロプライエタリー リミテッド 生長因子
US4863901A (en) * 1986-01-09 1989-09-05 Brigham & Women's Hospital Use of growth hormone for nitrogen retention under hypocaloric conditions
US4769361A (en) * 1986-08-07 1988-09-06 International Minerals & Chemical Corp. Method for purifying and isolating two ionic forms of somatomedin C
US4816439A (en) * 1987-03-27 1989-03-28 Nordiske Gentofte A/S The use of human growth hormone for the treatment of intoxicated individuals
US4833166A (en) * 1987-05-01 1989-05-23 Grosvenor Clark E Growth hormone releasing hormone complementary peptides
US4837202A (en) * 1987-09-14 1989-06-06 Pitman-Moore, Inc. Method for stimulating the immune system
US5028591A (en) * 1987-09-14 1991-07-02 Pitman-Moore, Inc. Method for stimulating the immune system
DE3852636T2 (de) * 1987-12-24 1995-05-04 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2).
US4939124A (en) * 1988-01-26 1990-07-03 Laboratorios Serono S.A. Treatment and diagnosis of dementia
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
NZ236618A (en) * 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
US5317012A (en) * 1991-10-04 1994-05-31 The University Of Tennessee Research Corporation Human growth hormone induced improvement in depressed T4/T8 ratio

Also Published As

Publication number Publication date
ATE152627T1 (de) 1997-05-15
FI935898A0 (fi) 1993-12-28
ES2101106T3 (es) 1997-07-01
EP0602050B1 (en) 1997-05-07
JPH06508830A (ja) 1994-10-06
US5583109A (en) 1996-12-10
AU655059B2 (en) 1994-12-01
DK0602050T3 (da) 1997-06-02
EP0602050A1 (en) 1994-06-22
FI935898A (fi) 1993-12-28
US5202119A (en) 1993-04-13
CA2109705A1 (en) 1993-01-07
DE69219607T2 (de) 1997-09-04
GR3024128T3 (en) 1997-10-31
AU2252592A (en) 1993-01-25
WO1993000110A1 (en) 1993-01-07
DE69219607D1 (de) 1997-06-12
NO934851D0 (no) 1993-12-27
NZ243232A (en) 1997-07-27

Similar Documents

Publication Publication Date Title
NO934851L (no) Fremgangsmåte for stimulering av immunrespons
IT1261949B (it) Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
ES2189790T3 (es) Curacion de heridas y tratamiento de trastornos fibroticos mediante tgf beta-3.
CA2101275A1 (en) Methods for the treatment of osteoporosis
KR950702120A (ko) 골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis)
DE69118978D1 (de) Behandlung von entzündlichen Erkrankungen mit 15-Ketoprostaglandinen
EP0251813A3 (en) Immunostimulating agents
IT8721616A0 (it) Procedimento per la preparazione dell'ormone della crescita umano
PL329077A1 (en) Method of treating cardiac insufficiency by means of endotelin antagonists
AU2085392A (en) Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
DE69032000D1 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
TW263437B (no)
NO925048D0 (no) Arylalkylestere av 4,5-dihydroksy-9,10-dihydro-9,10-diokso-2-antracenkarboksylsyre med terapeutisk aktivitet
IL103799A (en) Fish production
DE69023459D1 (de) Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten.
ATE59550T1 (de) Chlorpheniramine therapie.
EP0458537A3 (en) Therapeutic compound for the treatment of bronchitis
SU1069818A1 (ru) Способ профилактики гриппа
IT1251615B (it) Medicamento ad attivita' antielastasica.
ATE83931T1 (de) Methode fuer die behandlung von viraler gehirnentzuendung.
AU609435B2 (en) Prevention of bovine respiratory disease complex in cattle by administration of interferon
EP0965346A3 (en) Use of acetylated mannan derivatives for treating chronic respiratory diseases
NO940383L (no) Anvendelse av vekstfaktor IGF-I og/eller IGF-II